Literature DB >> 19303496

Effects of race and ethnicity on the incidence of venous thromboembolism.

Richard H White1, Craig R Keenan.   

Abstract

Although there is strong evidence that the prevalence of venous thrombo-embolism (VTE) varies significantly among different ethnic/racial groups, the genetic, physiologic and/or clinical basis for these differences remain largely undefined. African-American patients have a significantly higher rate of incident VTE, particularly following exposure to a provoking risk factor such as surgery, medical illness, trauma, etc. In addition, African-Americans are more likely to be diagnosed with pulmonary embolism (PE) than deep-vein thrombosis (DVT) compared to Caucasian and other racial groups. On the other extreme, Asians/Pacific Islanders have a 70% lower prevalence of VTE and this is true for both idiopathic VTE and provoked, or 'secondary', VTE. Hispanics have a significantly lower prevalence of VTE compared to Caucasians, but higher than Asians/Pacific Islanders. The incidence of recurrent VTE varies depending on gender, type of thromboembolic event and race. Further research is needed in order to determine the fundamental differences between racial/ethnic groups that explain the observed differences in the prevalence of VTE. Race/ethnicity should be considered an important factor in the risk-stratification of patients with suspected VTE or patients at some risk for developing VTE.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19303496     DOI: 10.1016/S0049-3848(09)70136-7

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  114 in total

1.  Race, ABO blood group, and venous thromboembolism risk: not black and white.

Authors:  Chunhui Fang; Hillel W Cohen; Henny H Billett
Journal:  Transfusion       Date:  2012-04-27       Impact factor: 3.157

Review 2.  The future of warfarin pharmacogenetics in under-represented minority groups.

Authors:  Larisa H Cavallari; Minoli A Perera
Journal:  Future Cardiol       Date:  2012-07

3.  Association of Apo(a)isoform size with dyslipoproteinemia in male venous thrombosis patients.

Authors:  Marian C Cheung; John J Albers; Hal Kennedy; Hiroshi Deguchi; Darlene J Elias; Patricia M Averell; John H Griffin; Santica M Marcovina
Journal:  Clin Chim Acta       Date:  2010-05-19       Impact factor: 3.786

4.  Racial and regional differences in venous thromboembolism in the United States in 3 cohorts.

Authors:  Neil A Zakai; Leslie A McClure; Suzanne E Judd; Monika M Safford; Aaron R Folsom; Pamela L Lutsey; Mary Cushman
Journal:  Circulation       Date:  2014-02-07       Impact factor: 29.690

5.  National and Regional Trends in Deep Vein Thrombosis Hospitalization Rates, Discharge Disposition, and Outcomes for Medicare Beneficiaries.

Authors:  Karl E Minges; Behnood Bikdeli; Yun Wang; Robert R Attaran; Harlan M Krumholz
Journal:  Am J Med       Date:  2018-06-23       Impact factor: 4.965

6.  Association of Genetic Variants With Warfarin-Associated Bleeding Among Patients of African Descent.

Authors:  Tanima De; Cristina Alarcon; Wenndy Hernandez; Ina Liko; Larisa H Cavallari; Julio D Duarte; Minoli A Perera
Journal:  JAMA       Date:  2018-10-23       Impact factor: 56.272

7.  Prevalence of death due to pulmonary embolism after trauma.

Authors:  Rodrigo Florêncio Echeverria; André Luciano Baitello; José Maria Pereira de Godoy; Paulo César Espada; Rogério Yukio Morioka
Journal:  Lung India       Date:  2010-04

8.  Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden.

Authors:  Mieke Van Hemelrijck; Jan Adolfsson; Hans Garmo; Anna Bill-Axelson; Ola Bratt; Erik Ingelsson; Mats Lambe; Pär Stattin; Lars Holmberg
Journal:  Lancet Oncol       Date:  2010-04-13       Impact factor: 41.316

Review 9.  Updated clinical recommendations for the use of tibolone in Asian women.

Authors:  K-E Huang; R Baber
Journal:  Climacteric       Date:  2010-08       Impact factor: 3.005

Review 10.  Review of venous thromboembolism and race: the generalizability of treatment guidelines for high-risk populations.

Authors:  Lonnie T Sullivan; Larry R Jackson; Kevin L Thomas
Journal:  J Thromb Thrombolysis       Date:  2016-08       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.